(Q46415474)

22 December 2017

title

Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance (English)

1 reference

22 December 2017

1 reference

1 reference

Cosson E

1

1 reference

22 December 2017

Bringuier AF

2

1 reference

22 December 2017

Paries J

3

1 reference

22 December 2017

Guillot R

4

1 reference

22 December 2017

Vaysse J

5

1 reference

22 December 2017

Attali JR

6

1 reference

22 December 2017

Feldmann G

7

1 reference

22 December 2017

Valensi P

8

1 reference

22 December 2017

publication date

1 February 2005

1 reference

22 December 2017

published in

Diabetes and Metabolism

1 reference

22 December 2017

volume

31

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

page(s)

47-54

1 reference

22 December 2017

Apoptosis in atherosclerosis: pathological and pharmacological implications.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Apoptosis in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Molecular mechanisms of aortic wall remodeling in response to hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Fas ligand-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Fas ligand in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Soluble Fas ligand and atherosclerosis in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Markers for silent myocardial ischemia in diabetes. Are they helpful?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Silent myocardial ischemia in patients with diabetes: who to screen

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD)

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble Fas levels and pathological findings

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Soluble Fas: a novel predictor of atherosclerosis in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Inflammatory parameters are independent predictors of severe epicardial coronary stenosis in asymptomatic diabetic patients with silent myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Mechanical stress-induced apoptosis in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Activation of the Fas/Fas ligand pathway in hypertensive renal disease in Dahl/Rapp rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

Contribution of Fas to diabetes development

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

C-reactive protein and glycemic control in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970166-0

7 January 2021

10.1016/S1262-3636(07)70166-0

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017